Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2013
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Hypereosinophilic syndrome; Polycythaemia vera
- Focus Therapeutic Use
- 11 Dec 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 05 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 04 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.